Clinical Islet Transplantation Consortium (CITC)

General Description

The CIT consortium conducted a total of 9 studies across North America (CIT02 through CIT08) and the Nordic region (CIT01). CIT08 was a long-term follow-up study for interested participants at the North American sites. The target population is individuals with type 1 diabetes, normal kidney function, and intractable hypoglycemia. All studies treated participants with up to 3 separate infusions of islets.

Related Studies

Acronym	Name
CIT-05/08	B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression
CIT-07/08	Islet Transplantation in Type 1 Diabetes
CIT-04/08	Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy
CIT-06/08	Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation
pan-CIT	Panoramic CIT Data
CIT-03/08	Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes and Extended Follow Up after Islet Transplantation in Type 1 Diabetes
CIT-01	Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
CIT-02/08	Strategies to Improve Long Term Islet Graft Survival and Extended Follow Up after Islet Transplantation in Type 1 Diabetes

Objectives

The studies investigated methods to improve the safety and efficacy of islet transplantation in treating patients with type 1 diabetes, with and without the complication of kidney failure.

Criteria

Individuals diagnosed with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28 were eligible for enrollment in the CITC studies. Specific inclusion and exclusion criteria for each of the studies are available on the individual study pages.

Outcome

Many studies have been recently concluded or are ongoing.